A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

Description

Purpose: To decrease symptom burden, improve cognitive function, improve endurance, and decrease fatigue in subjects with post-acute sequelae of COVID-19 (PASC) or "long-hauler" COVID using amantadine. If amantadine use is determined to be efficacious in this population, the findings of this study will be used towards a subsequent randomized control trial.

Conditions

Long COVID, Post-Acute COVID-19 Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

Purpose: To decrease symptom burden, improve cognitive function, improve endurance, and decrease fatigue in subjects with post-acute sequelae of COVID-19 (PASC) or "long-hauler" COVID using amantadine. If amantadine use is determined to be efficacious in this population, the findings of this study will be used towards a subsequent randomized control trial.

Feasibility Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid: A Pilot Randomized Control Trial

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

Condition
Long COVID
Intervention / Treatment

-

Contacts and Locations

Dallas

UT Southwestern Medical Center, Dallas, Texas, United States, 75390

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 20-65
  • * Can provide informed consent
  • * Confirmed COVID+ test (either rapid antigen or PCR) between 8 weeks and one year prior to initial visit.
  • * Able to consent in English
  • * Endorse symptoms during their initial evaluation and history with the provider that began around the time of the acute COVID19 infection (subjective) including cognitive changes such as cognitive fatigue, brain fog, memory issues,attention issues AND have symptoms in at least 1 out of the 2 following symptom categories:
  • * Category 1: Decreased endurance, physical fatigue, weakness
  • * Category 2: Depression, anxiety
  • * Known hypersensitivity to amantadine
  • * Clinically significant psychiatric, neurologic, renal, hepatic, opthalmologic, cardiac impairment in the opinion of the investigators, including but not limited to:
  • * Psychiatric:
  • * Acute or chronic unstable Axis I psychiatric illness
  • * History of psychosis
  • * Severe depression Patient Health Questionnaire-9 (PHQ-9) score \>= 20
  • * Suicidality
  • * Neurologic:
  • * Epilepsy
  • * Cognitive dysfunction predating COVID infection
  • * History of delirium
  • * Neurologic conditions with agitation or confusion

Ages Eligible for Study

20 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Texas Southwestern Medical Center,

Amy Mathews, M.D., PRINCIPAL_INVESTIGATOR, UT Southwestern Medical Center

Study Record Dates

2025-06-01